Ideaya Biosciences Inc [IDYA] stock is trading at $21.85, up 0.55%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IDYA shares have gain 5.25% over the last week, with a monthly amount drifted -5.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ideaya Biosciences Inc [NASDAQ: IDYA] stock has seen the most recent analyst activity on November 18, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $51. Previously, Leerink Partners downgraded its rating to Market Perform on November 05, 2024, and kept the price target unchanged to $27. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Mizuho initiated its recommendation with a Outperform and recommended $50 as its price target on July 08, 2024. BTIG Research started tracking with a Buy rating for this stock on March 08, 2024, and assigned it a price target of $55. In a note dated August 08, 2023, SVB Securities initiated an Outperform rating and provided a target price of $33 on this stock.
Ideaya Biosciences Inc [IDYA] stock has fluctuated between $19.96 and $47.72 over the past year. Currently, Wall Street analysts expect the stock to reach $52.29 within the next 12 months. Ideaya Biosciences Inc [NASDAQ: IDYA] shares were valued at $21.85 at the most recent close of the market. An investor can expect a potential return of 139.31% based on the average IDYA price forecast.
Analyzing the IDYA fundamentals
Ideaya Biosciences Inc [NASDAQ:IDYA] reported sales of 7.00M for the trailing twelve months, which represents a growth of 78.43%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -46.71%, Pretax Profit Margin comes in at -39.21%, and Net Profit Margin reading is -39.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.27 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.35 points at the first support level, and at 20.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.38, and for the 2nd resistance point, it is at 22.92.
Ratios To Look Out For
For context, Ideaya Biosciences Inc’s Current Ratio is 14.97. Also, the Quick Ratio is 14.97, while the Cash Ratio stands at 1.83. Considering the valuation of this stock, the price to sales ratio is 273.24, the price to book ratio is 1.78.
Transactions by insiders
Recent insider trading involved Jason Throne, Former Officer, that happened on Aug 26 ’24 when 75000.0 shares were purchased. Chief Scientific Officer, WHITE MICHAEL ANTHONY completed a deal on May 29 ’24 to sell 28500.0 shares. Meanwhile, President and CEO Hata Yujiro S sold 83856.0 shares on May 15 ’24.
